Newron Pharmaceuticals (SWX: NWRN)

Last close As at 03/11/2026

CHF8.96

▲ 0.12 (1.36%)

Market capitalisation

CHF191m

Newron Pharmaceuticals is focused on the central nervous system. Xadago for Parkinson’s disease is sold in Europe, Japan and the United States. Evenamide, a novel schizophrenia add-on therapy, is involved in a Phase III trial programme targeting treatment-resistant schizophrenia.

EDISON VIEW

Newron Pharmaceuticals has completed ENIGMA-TRS 1 enrolment in treatment-resistant schizophrenia (TRS), with 618 patients randomised and pivotal 12-week data expected in Q127. This removes recruitment uncertainty, although the FDA’s US clinical hold on ENIGMA-TRS 2 remains unresolved. The hold concerns potential arrhythmic risk linked to evenamide’s sodium channel blockade, following four deaths among treated patients across ENIGMA-TRS 1 and Phase II 014/015, versus one on placebo. However, only one was considered possibly treatment-related, and Newron reports lower exposure-adjusted mortality than placebo, alongside no consistent cardiac safety signal. Management has now proposed enhanced cardiac screening and monitoring, including genetic testing for Brugada syndrome. We view these measures as constructive, although regulatory acceptance remains critical. With Newron targeting an end-October response to the FDA and ENIGMA-TRS 2 continuing ex-US, we retain our 2029 US launch assumption and CHF20.9/share valuation.

Q&A

What does Newron Pharmaceuticals do and how does it make money?

Newron Pharmaceuticals is a biopharmaceutical company headquartered in Bresso, near Milan, focused on conditions of the central nervous system (CNS). It makes money from recurring royalty income on Xadago (safinamide), a Parkinson's disease treatment commercialised through regional partners including Zambon, Supernus Pharmaceuticals and Meiji Seika Pharma. It also has some licensing revenue from evenamide, which is being developed for treatment-resistant schizophrenia (TRS). For evenamide, its December 2024 licence with EA Pharma, a subsidiary of Eisai, covering Japan and selected Asian territories, is worth up to €117m in upfront and milestone payments, plus tiered royalties. Evenamide is a first-in-class glutamate modulator being developed as an add-on therapy for schizophrenia, specifically looking at TRS, and is the company's principal clinical and valuation driver.

What drives the investment case for Newron Pharmaceuticals, and what are the main risks?

The investment case for Newron Pharmaceuticals rests on evenamide in treatment-resistant schizophrenia, and we view the Q127 ENIGMA-TRS 1 readout as the most significant near-term value inflection point. FDA acceptance of the proposed cardiac risk-mitigation measures is equally important for development visibility. At 22 October 2026, the US clinical hold on ENIGMA-TRS 2, which concerns potential arrhythmic risk from evenamide's sodium channel blockade, remained unresolved, with Newron targeting an end-October response to the FDA and ENIGMA-TRS 2 recruiting outside the US. The FDA highlighted four deaths among evenamide-treated patients across the clinical programme, versus one on placebo; none occurred in ENIGMA-TRS 2, three were considered unrelated to treatment by investigators, and the remaining death was classified as possibly related because a definitive cause could not be established. Crude mortality was numerically higher on evenamide (0.56% versus 0.27%), but exposure-adjusted mortality favoured it (1.31 versus 1.81 deaths per 100 patient-years). A predominantly ex-US pivotal dataset adds FDA acceptance risk.

What are the forecasts for Newron Pharmaceuticals?

Our forecasts for Newron Pharmaceuticals show revenue of €12.6m in FY26 and €46.7m in FY27 (years to end-December), with normalised PBT losses of €30.0m and €3.2m, respectively. The FY26 estimate includes the €5.5m milestone payment received from EA Pharma in September 2026. FY27 includes c €7.1m of Xadago royalties and risk-adjusted income from our assumed European licensing transaction for evenamide. The rephasing of ENIGMA-TRS 2 costs into FY27 results in a higher FY27 operating cost base than we previously anticipated, so FY27 remains particularly sensitive to the timing and economics of any European licensing agreement and to the pace of ENIGMA-TRS 2 execution. At 22 October 2026, with the FDA's US clinical hold on ENIGMA-TRS 2 unresolved, we retained these estimates and will reassess them as greater clarity emerges on the FDA's decision and subsequent clinical progress.

How is Newron Pharmaceuticals valued?

On our risk-adjusted net present valuation, Newron Pharmaceuticals is valued at CHF444.2m, or CHF20.9 per share, with a 70% probability of success applied to evenamide. We assume a US launch in 2029 following a New Drug Application (NDA) filing in early 2028, a one-year delay that already allows for the FDA clinical hold on ENIGMA-TRS 2. The effect of the later launch on the risk-adjusted valuation was largely offset by a longer patent runway, with European protection scheduled to October 2044.

What revenue does Newron Pharmaceuticals generate?

Newron Pharmaceuticals generated revenue of €19.1m in FY25, versus €51.4m in FY24. The FY24 figure benefited from the €44m upfront payment from EA Pharma. In FY25, Xadago royalty income from Zambon was €7.8m and licensing income was €8.6m, of which we understand c 70% related to EA Pharma and 30% to Myung In Pharm. In H126, revenue fell 73.2% to €3.2m from €11.9m in H125, which had benefited from €7.8m of licence income, and Xadago royalties of €3.1m provided most of the H126 total. We expect Xadago's contribution to moderate as the franchise matures, particularly after the earliest permitted entry of generic safinamide in the US from December 2027.

When will Newron Pharmaceuticals report the ENIGMA-TRS Phase III results?

Newron Pharmaceuticals expects 12-week ENIGMA-TRS 1 results, from 618 patients randomised across Europe, Asia, Latin America and Canada, in Q127. For ENIGMA-TRS 2, which targets 400 patients, the company's working expectation is a Q327 top-line readout, and resolving the FDA's clinical hold would dictate whether it is met. The hold covers US recruitment for ENIGMA-TRS 2; the study continues to recruit in Asia and Latin America, although it remains unclear whether the enhanced cardiac screening requirements will extend to non-US sites, which could affect the ENIGMA-TRS 2 timeline. At 22 October 2026, Newron was targeting its revised response to the FDA by end-October.

How long can Newron Pharmaceuticals fund its operations?

We estimate that the pro forma cash position of c €43.9m at end-June 2026 should support Newron Pharmaceuticals' operations through Q327, potentially covering both pivotal readouts, although resolving the FDA's clinical hold would dictate whether ENIGMA-TRS 2 meets its Q327 readout timeline. Management expects current resources to support operations through most of 2027. It also expects a further €5.5m equity tranche by 30 November 2026, which we model as illustrative debt pending issuance. The remaining €12m of the €38m equity financing secured in February 2026 could extend the runway towards end-2027, but it is contingent on positive ENIGMA-TRS readouts. At 22 October 2026, with the FDA's US clinical hold on ENIGMA-TRS 2 unresolved, we noted that additional cardiac screening costs and prolonged US recruitment delays could increase funding requirements, although we believe existing liquidity reduces immediate financing pressure ahead of the Q127 ENIGMA-TRS 1 readout.

Does Newron Pharmaceuticals pay a dividend?

Newron Pharmaceuticals does not pay a dividend.

Equity Proposition

Newron Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing novel therapies for central nervous system (CNS) disorders. The company is progressing its lead asset, evenamide, through late-stage development for treatment-resistant schizophrenia (TRS), a disease area with limited innovation in recent years and, hence, one with a potentially sizable commercial opportunity.

There are five key reasons why Newron may be considered a compelling investment opportunity:

1. Addressing a major unmet need in healthcare.

Schizophrenia remains one of the most challenging psychiatric disorders, with many patients failing to adequately control symptoms despite current therapies. While antipsychotics have transformed treatment, many patients continue to experience persistent symptoms, and there are currently no approved add-on therapies specifically for TRS. This represents a significant unmet need and an attractive opportunity for innovation. Interest in novel CNS assets has also strengthened as pharma companies seek differentiated late-stage programmes for underserved patient populations. Schizophrenia represents a sizable market, and therapies showing meaningful benefit have historically achieved blockbuster sales. If successfully developed, evenamide has the potential to address this opportunity with limited direct competition.

 2. Evenamide is supported by encouraging clinical data in TRS.

Evenamide is being developed as an add-on therapy for patients with TRS, a population poorly served by current treatment options. Evenamide has a novel mechanism of action, targeting glutamate signalling (a key pathway involved in brain function that is not directly addressed by most existing antipsychotics), which may allow it to complement existing treatments. Top-line results from the prior TRS clinical trial showed that more than 70% of patients achieved a clinically meaningful reduction in condition severity, c 50% of patients no longer met the protocol severity criteria for a diagnosis of TRS and 25% of patients were described as achieving clinical remission. These findings provide a supportive foundation for the subsequent registrational programme.

3. Defined path through registrational development with upcoming catalysts.

Evenamide is progressing through the registrational ENIGMA-TRS programme. The two associated studies (ENIGMA-TRS 1 and ENIGMA-TRS 2) are expected to build on the encouraging data generated to date. Top-line results from the first of these studies are anticipated in Q426, representing a significant upcoming potential catalyst. In addition, potential further partnering discussions may provide incremental value drivers as the programme advances.

4. Strategic partnerships provide external validation of evenamide’s potential.

Newron has already secured regional licensing agreements for evenamide with EA Pharma in Japan and Myung In Pharm in South Korea. These deals provide third-party validation of the asset’s potential, particularly given the complexity and risk associated with CNS drug development. Beyond validation, these partnerships offer access to local development expertise and potential commercial infrastructure in key markets, while also providing financial support through upfront payments, milestones and future royalties. This approach may allow Newron to retain strategic flexibility while advancing the programme globally.

5. Proven commercial capabilities.

Newron’s marketed Parkinson’s disease therapy, Xadago, demonstrates the company’s ability to successfully develop and commercialise a CNS drug. Xadago’s approval provides validation of Newron’s development capabilities and a degree of revenue visibility. This established commercial foundation differentiates Newron from earlier-stage peers and may support future execution as pipeline assets approach the market. It also highlights management’s experience in navigating the regulatory and commercial pathways within complex neurological indications.

In summary, Newron Pharmaceuticals presents a focused investment case centred on evenamide in TRS, supported by encouraging clinical data, external validation through partnerships, a clear development pathway and an established commercial track record. Together, these elements underpin the company’s positioning within the CNS-focused biotechnology landscape.

Published 17 July 2026

Latest Insights

View More

Market Data

Share Price CHF8.96
Market Cap CHF191m
52-Week High CHF31.85
52-Week Low CHF5.72
% Change 1M 14.9
% Change 6M (35.1)
% Change 12M (36.5)
Ave. Daily Volume 1yr 95,252

Sector

Healthcare

Equity Analyst

Key Management

  • Roberto Galli

    CFO

  • Stefan Weber

    CEO

  • Ravi Anand

    CMO

Share Price Chart

Further insights

insight

Healthcare

Newron Pharmaceuticals: EKF 2023 QuickView

EKF QuickView - Edison Group

insight

Healthcare

Deutsches Eigenkapitalforum (EKF) 2022 healthcare

EKF QuickView - Edison Group

insight

Consumer

Deutsches Eigenkapitalforum (EKF) 2022

Thematics

Cookie Policy Overview
Edison Group

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping us understand which section of the website you find more interesting and useful. See our Cookie Policy for more information.

Strictly necessary and functional

These cookies are used to deliver our website and content. Strictly necessary cookies relate to our hosting environment, and functional cookies are used to facilitate social logins, social sharing and rich-media content embeds.

Advertising

Advertising Cookies collect information about your browsing habits such as the pages you visit and links you follow. These audience insights are used to make our website more relevant.

Performance

Performance Cookies collect anonymous information designed to help us improve the site and respond to the needs of our audiences. We use this information to make our site faster, more relevant and improve the navigation for all users.